Benicar, Azor & Tribenzor Sprue-like Enteropathy

Drug Liability Attorneys in New York City

The FDA issued a safety warning in July 2013 that the blood pressure drug Benicar (generic name olmesartan medoxomil) has been linked to sprue-like enteropathy. Our firm was the first to file Benicar suits and continues to aggressively litigate for Benicar victims. Partners Paul Rheingold and David Rheingold are all part of the Benicar federal litigation team. We have instituted a dual litigation strategy, aggressively pushing suits in both federal and state courts. At Rheingold Giuffra Ruffo & Plotkin LLP, our New York defective drug lawyers handle cases directly and do not refer them to other firms.

Contact us to speak with a drug litigation partner from a
New York pharmaceutical litigation law firm.

Mayo Clinic Sounds Alarm for Injuries Caused by Benicar

A Japanese company, Daiichi Sankyo, created Benicar and marketed it in the United States through Forest Laboratories. Both companies came under FDA scrutiny for overpromotion and illegal kickbacks, with fines levied. As early as 2009, the FDA was inquiring about unusually high numbers of adverse event reports involving diarrhea, misdiagnosed as celiac disease. Daiichi denied any connection to Benicar, but in 2012 the Mayo clinic reported on 22 patients who had developed this severe sprue-like enteropathy who had used Benicar for over three years. These people had mucosal inflammation, villous atrophy and collagen deposits.

Symptoms of sprue-like enteropathy can include:

  • Abdominal pain
  • Severe diarrhea
  • Chronic diarrhea
  • Fatigue
  • Weight loss
  • mucosal inflammation
  • villous atrophy
  • collagen deposits

Our litigation partners personally work with clients to determine the extent of the monetary damage this drug has caused them, and what legal remedies are at their disposal.

firm experienced in dealing with PHARMACEUTICAL companies

Our firm has extensive litigation experience against Japanese pharmaceutical companies. In the 1990s, senior partner Paul Rheingold litigated against Showa Denko, the maker of l-tryptophan which was laced with impurities causing eosinophilia-myalgia syndrome, a potentially fatal muscle and blood ailment. More recently, we represented clients with bladder cancer caused by Actos, made by Tekada Pharmaceuticals, another Japanese company.

Our New York defective drug attorneys are able to handle a wide range of drug liability claims, including those involving the prescription drug Benicar. Call (888) 260-0473 for a free case evaluation.

Results Feed Header

Prev Next

Don't Settle

for an Average Attorney
    • Please enter your name.
    • This isn't a valid phone number.
    • Please enter your email address.
      This isn't a valid email address.
    • Please make a selection.
    • Please enter a message.
Get RGRP On Your Side